RLAY: רווח נקי למניה ב-12 החודשים האחרונים relaytx.com
The reliability of Relay Therapeutics (RLAY) is based on its partnership with Roche and the monetization of the Dynamite AI system. The annual EPS TTM snapshot clearly confirms this stability, where the value -1.52 serves as the baseline metric. The efficiency of digital drug design and the diversification of clinical programs through IT protein modeling create additional benchmarks for long-term investment in precision oncology.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_RLAY_-_Relay-Therapeutics_-_Earnings-per-share-for-the-last-four-quarters "Relay Pharma - רווח נקי למניה (EPS TTM) RLAY (תקופה 04.07.2022 - 12.11.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים של חברת Relay Therapeutics
The development of targeted therapies for rare cancers makes the survival of Relay Therapeutics (RLAY) dependent on FDA verdicts, which directly impacts its financial stability. By analyzing the 12-month earnings per share history, an investor assesses the real return per share, adjusted for equity dilution, to determine the business's margin of safety amid expensive borrowing and liquidity freeze risks.
